Warm hemolytic anemia is a rare condition that affects your red blood cells. It causes anemia-like symptoms, such as fatigue, jaundice, and paleness. Share on Pinterest ZeynepKaya/Getty Images In warm ...

A newly published case report suggests sutimlimab (Enjaymo) may be an effective treatment for some patients with warm autoimmune hemolytic anemia (wAIHA). Sutimlimab is a humanized monoclonal antibody ...

Rigel Pharmaceuticals, Inc. today announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm ...

LAS VEGAS, June 30, 2026 /PRNewswire/ -- Recently published Warm Autoimmune Hemolytic Anemia Market Insights report includes a comprehensive understanding of current treatment practices, warm ...

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Phase 2b LUMINA 2 study data support rilzabrutinib's FDA Breakthrough Therapy designation for the treatment of warm autoimmune hemolytic anemia. The Food and Drug Administration (FDA) has granted ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

(RTTNews) - HUTCHMED (China) Ltd. (HCM) on Wednesday announced that Phase III registration part of its ESLIM-02 clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic ...

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias. Neil Minkoff, MD: Now, you had mentioned that there are other autoimmune ...

Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive therapies such as corticosteroids, rituximab, and other nonspecific agents.